NR3C1 and urinary bladder cancer: In fact, in GR-positive bladder cancer cells, a GR-agonist (dexamethasone) significantly reduced the expression of CD44, transcription factors, including β-catenin and its downstream target (C-MYC, Snail, and OCT-4), the rate of sphere formation, and the proportion of side populations, and induced the intracellular levels of reactive oxygen species.